Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
enzyme disorders
Biotech
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
BioMarin is paying $70M upfront to license a next-generation Fabry disease therapy, expanding its franchise following the $4.8B Amicus takeover.
Nick Paul Taylor
Oct 29, 2026 10:13am
Ambrose inks $181M deal for former Pfizer target AM-Pharma
Oct 20, 2026 2:00am
Genentech pays Alector $100M for preclinical Parkinson’s asset
Oct 5, 2026 10:09am
BioMarin axes $270M asset after missing phase 3 endpoint
Aug 7, 2026 9:10am
GSK won't pick up Wave's genetic disease RNA editor
Feb 2, 2026 11:14am
Denali ph. 1 Pompe plans hit with clinical hold
Dec 4, 2025 11:52am
